Merck & Co Inc
MRK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$559.00 | Glsp | Pjqwvmkkw |
Merck: Posts Leading Early-Stage Keytruda Data in Lung Cancer, Creates Important Daiichi Partnership
We are holding firm to our Merck fair value estimate following the presentation of leading efficacy data for Keytruda in periadjuvant non-small-cell lung cancer and the announcement of a partnership with Daiichi for three new antibody-drug conjugates. Merck's continued strong innovation with Keytruda and fair deployment of capital reinforce its wide moat.